Metraipolis › archive › dc_1077b87359da
Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database — Europe PMC PMID:41357880
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41357880
- DOI
- 10.3389/fphar.2025.1713170
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T09:16:06.312Z
- SHA-256 of the archived text
d45fcd99b076ffe2b74622753fe07b2aca763eb440be0593f3e285780873cda6- Stable URL of this page
https://metraipolis.com/documento/dc_1077b87359da
How to cite
Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database — Europe PMC PMID:41357880 — Europe PMC (en), https://europepmc.org/article/MED/41357880 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1077b87359da (Metraipolis archive dc_1077b87359da, sha256 d45fcd99b076ffe2b74622753fe07b2aca763eb440be0593f3e285780873cda6)
BibTeX
@misc{dc1077b87359da,
title = {Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database — Europe PMC PMID:41357880},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41357880},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1077b87359da; sha256 d45fcd99b076ffe2b74622753fe07b2aca763eb440be0593f3e285780873cda6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41357880. Agents can read the archived copy with the MCP tool read_document.